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Prevalence of dyslipidemic risk factors in hemodialysis and but cardiovascular disease (CVD) develops very prema-
CAPD patients. turely [1]. Besides hypertension, diabetes mellitus, hyper-
Background. Dyslipidemic factors obviously contribute to homocysteinemia, left ventricular hypertrophy, smoking,the high cardiovascular risk in dialysis patients but are often
increased oxidative stress, inflammation, and malnutri-an underestimated problem. Therefore, we determined the
tion, dyslipidemic factors obviously contribute to this highprevalence of dyslipidemic factors in a large group of unse-
lected hemodialysis (N  564) and CAPD (N  168) patients. risk [2, 3]. We investigated the prevalence of these dyslip-
Methods. We used the recently published recommendations idemic factors, defined by the recent recommendations
of the Medical Experts Group concerning cardiovascular risk
of the Medical Expert Group [4], in a large group offactors for the categorization of dyslipidemic factors. These
unselected hemodialysis (HD) and CAPD patients. Fur-were total cholesterol 200 mg/dL, low-density lipoprotein
(LDL) cholesterol 100 mg/dL, high-density lipoprotein (HDL) thermore, we analyzed apolipoprotein A-IV (apoA-IV),
cholesterol 40 mg/dL, triglycerides 180 mg/dL, and Lp(a) which was recently shown to be associated with cardio-
30 mg/dL. vascular disease in the general population [5, 6], as wellResults. CAPD patients had, in sum, a markedly worse lipid
as in patients with mild and moderate renal failure [7].profile when compared with HD patients. They had higher
frequencies of elevated total cholesterol (67% vs. 34%), triglyc-
erides (47% vs. 28%), and Lp(a) concentrations (37% vs. 30%)
METHODSwhen compared with HD patients. In both patient groups,
about two thirds of the patients had LDL cholesterol above Patients
100 mg/dL and HDL cholesterol below 40 mg/dL. When we
A total of 702 adult white dialysis patients from sevenanalyzed the total frequency of dyslipidemic factors, we ob-
served that the CAPD group included a markedly higher num- renal units were enrolled in this study. They had been
ber of patients with three or four concurrent dyslipidemic fac- dialyzed for at least three months. The detailed character-
tors than HD patients (P  0.001). Furthermore, we analyzed istics are described in an earlier study [8]. Briefly, the HDapolipoprotein A-IV (apoA-IV), which was recently shown to
group included 534 patients (57% males) with a mean agebe associated with cardiovascular disease, and which was about
of 54.1  15.9 years and a mean duration of HD treat-twice as high in both patient groups when compared with con-
trols (P  0.001). ment of 33  36 (range, 3–230) months. Dialysis was per-
Conclusions. Dyslipidemic risk factors are highly prevalent formed three times weekly for 3.9 hours on average. The
in dialysis patients, and the concomitant occurrence of several
CAPD group comprised 168 patients (54% males) withrisk factors in a given patient is more often observed in CAPD
a mean age of 53.1  15.1 years and a mean duration ofthan HD patients.
CAPD treatment of 21  29 (range, 3–176) months. The
frequency of patients with diabetic nephropathy was 18%
and 39%, respectively. The control group for comparisonPatients with chronic kidney disease have one of the
highest risks for atherosclerotic complications known. of apoA-IV levels consisted of 256 healthy individuals
The cardiovascular mortality is not only increased 10- selected from a group of consecutive blood donors.
to 20-fold when compared with the general population,
Laboratory procedures
Ethylenediaminetetra-acetic acid (EDTA) plasma wasKey words: cardiovascular disease, dialysis, lipids, lipoprotein(a), apoli-
poprotein A-IV, dyslipidemia. taken after a 12-hour overnight fast before dialysis of HD
patients, or during a visit in the outpatient department 2003 by the International Society of Nephrology
S-113
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Table 1. Mean ( SD) plasma lipids, lipoprotein(a), and
apolipoprotein A-IV in hemodialysis and CAPD patients
Hemodialysis CAPD
N  534 N  168
Total cholesterol mg/dL 18454 23066a
Triglycerides mg/dL 163185 194112a
HDL cholesterol mg/dL 37.514.6 36.913.0
LDL cholesterol mg/dL 11544 15555a
Total/HDL cholesterol ratio 5.542.98 6.993.39a
Lp(a) mg/dL 23.425.0 34.638.4a
Apo A-IV mg/dL 30.28.3 30.99.4
Unadjusted data of the above variables were used for comparison between
hemodialysis and CAPD patients since no differences for sex and age were
observed between the two groups. Therefore, minor differences to our previous
work [8] can be seen, in which we used age- and sex-adjusted variables because
of differences of these two variables when compared to the control group.
aP  0.001 for comparison with hemodialysis patients
in CAPD patients. Plasma concentrations of Lp(a) and
apo A-IV were measured by ELISA technique as pre-
viously described [9]. Total cholesterol, HDL choles-
terol, triglycerides, and albumin were determined using
kits from Roche (Mannheim, Germany). LDL choles-
terol was calculated using the Friedewald formula.
Statistical procedures
Comparison of continuous variables was performed
by t test or by the nonparametric Wilcoxon rank sum
test in case of non-normally distributed variables (Lp(a)
and triglycerides). We used the recently published rec-
ommendations of the Medical Experts Group concern-
ing cardiovascular risk factors [4] for the categorization
of dyslipidemic factors. These were total cholesterol
200 mg/dL, LDL cholesterol 100 mg/dL, HDL cho-
lesterol 40 mg/dL, and triglycerides 180 mg/dL. Fur-
thermore, Lp(a)30 mg/dL was considered a risk factor. Fig. 1. Prevalence of dyslipidemic factors in hemodialysis (HD) and
CAPD patients. The definition of dyslipidemic factors is based on recentDifferences in the frequencies of dyslipidemic factors
recommendations of the Medical Expert Group [4]. (A) The prevalencebetween HD and CAPD patients were compared by of elevated total and LDL cholesterol, triglycerides, and Lp(a) levels
Pearson’s 2 test. The same test was used to compare and decreased HDL cholesterol levels for HD and CAPD patients. (B)
The frequency of concomitant dyslipidemic risk factors in each patientthe distribution of apoA-IV concentrations between the
for HD and CAPD patients. For the sum of these risk factors we
two patient groups and controls. Statistical analysis was considered LDL, HDL cholesterol, triglycerides, and Lp(a). The fre-
quency of concomitant dyslipidemic risk factors was significantly differ-performed with Statistical Package for the Social Sci-
ent between the two treatment groups (2  37.0, df  4, P  0.001).ences (SPSS, SPSS Inc., Chicago, IL) for Windows 11.0.
RESULTS
Patients treated by CAPD had, in sum, a markedly 1A). In both patient groups, about two thirds of the
worse lipid profile when compared to HD patients: they patients had LDL cholesterol levels above 100 mg/dL
had higher total and LDL cholesterol levels and higher and HDL cholesterol below 40 mg/dL. Triglyceride con-
triglyceride plasma concentrations. Furthermore, Lp(a) centrations above 180 mg/dL were observed in 47% of
was markedly higher in CAPD patients (Table 1). the CAPD patients, and 28% of the hemodialysis pa-
When we used the definitions of dyslipidemic factors tients. Lp(a) concentrations above 30 mg/dL were ob-
as recently described [4], we observed in CAPD patients served in 37% and 30% of HD and CAPD patients,
twice the frequency of total cholesterol above 200 mg/dL respectively.
We analyzed the concomitant frequency of dyslipi-when compared to HD patients (67% vs. 34%) (Fig.
Kronenberg et al: Dyslipidemic risk factors in dialysis patients S-115
uremic dyslipidemia elevated triglyceride concentrations,
but not the other manifold changes (e.g., elevated inter-
mediate density lipoproteins and a disturbed lipolysis,
increase of small dense LDL, disturbances of the reverse
cholesterol transport). We therefore used the recent rec-
ommendations of the Medical Experts Group defining
dyslipidemic factors to investigate the prevalence of dys-
lipidemic factors in a large group of unselected HD and
CAPD patients. These recommendations are based on the
assumption that dialysis patients are, irrespective of lipid
levels, the group with the highest known risk of developing
cardiovascular disease [4, 12]. Therefore, the criteria and
treatment goals are very stringent to achieve LDL choles-
terol and triglyceride target levels, irrespective of whether
symptomatic ischemic heart disease is present [4].
Using these recommendations, we observed a veryFig. 2. Frequency distribution (%) of apolipoprotein A-IV (apoA-IV)
high prevalence of risk factors, which were mainly LDLplasma concentrations in patients with end-stage renal disease treated
by hemodialysis (HD) (N  534) or continuous ambulatory peritoneal cholesterol above 100 mg/dL and HDL cholesterol below
dialysis (CAPD) (N  168) and 256 healthy controls. Pearson’s 2 test: 40 mg/dL, in about two thirds of both patient groups (Fig.HD vs. controls, P 0.001; HD vs. CAPD, PNS, CAPD vs. controls,
1A). This results in pathologic LDL to HDL cholesterolP  0.001.
ratios in many patients. Triglyceride concentrations
above 180 mg/dL were also prevalent in about half of
the CAPD patients, but only one quarter of the HD
demic factors, considering LDL and HDL cholesterol, patients. The disturbing fact is that about half of the
triglycerides, and Lp(a) in each patient. We did not in- CAPD patients and a quarter of the HD patients have
clude total cholesterol in this analysis, due to the high three or four dyslipidemic factors at the same time, and
correlation with LDL cholesterol. Using this dyslipi- only a small number of patients has no such disturbances
demic score, we found major differences between HD (Fig. 1B). Furthermore, about 70% of the HD patients
and CAPD patients. The CAPD group included a mark- and more than 90% of the CAPD patients would require
edly higher number of patients with three or four dyslipi- interventions (lifestyle changes and/or lipid-lowering
demic factors, and a lower number of those with a low drugs) to achieve the target levels for LDL cholesterol
dyslipidemic score when compared to HD patients (2 and triglycerides.
37.0, df 4, P 0.001) (Fig. 1B). To achieve an optimal Most of the earlier studies showed that lipids are not
level of LDL cholesterol 100 mg/dL and triglycerides predictive for cardiovascular disease in dialysis patients.
180 mg/dL, 70.4% of the HD patients and 91.7% of However, this does not mean that they are not contribut-
the CAPD patients would require lifestyle changes (e.g., ing to the tremendous cardiovascular risk. The low pre-
diet, weight reduction, increase of physical activity) dictive properties can probably be explained by the mani-
and/or lipid-lowering drug treatment (P  0.001). fold changes of lipids and apolipoproteins during the
Finally, we investigated the apoA-IV plasma concen- different stages of renal disease, and that any lipid con-
trations in both patient groups and compared it to a centration presents only a snapshot at a given time, which
control group of healthy blood donors. ApoA-IV was does not reflect the development over time as recently
about twice as high in both patient groups when com- discussed [13, 14]. By measuring the lipid profile we
probably do not get sufficient information about the realpared to controls (Table 1). When we analyzed the distri-
atherogenicity. Better tools for the prediction of cardio-bution of apoA-IV plasma concentration in the three
vascular disease might be time-integrated lipid valuesgroups, we observed a similar distribution in HD and
(area under the time-lipid curve), postprandial dyslipide-CAPD patients, but major differences when compared
mia, or genetic factors, such as the apo(a) K-IV repeatto the controls (P  0.001) (Figure 2).
polymorphism [13, 15]. However, some of these parame-
ters are hard to obtain. Future studies should focus on
DISCUSSION the development of better tools to achieve information
For a long time, dyslipidemic changes in dialysis pa- on these parameters. In the meantime, we are eagerly
tients were an underestimated problem. This was mainly awaiting and demanding ongoing interventional studies
caused by the fact that hemodialysis patients have, on with lipid-lowering drugs in renal patients [16], which
average, normal or even subnormal total and LDL cho- will show whether these interventions decrease the num-
ber of cardiovascular events in these patients.lesterol levels [10, 11]. Most physicians combine with
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poprotein A-IV plasma concentrations in men with coronary arteryOne of the newer parameters related to atherosclero-
disease. J Am Coll Cardiol 36:751–757, 2000
sis we tested was apoA-IV. This apolipoprotein is in- 6. Warner MM, Guo J, Zhao Y: The relationship between plasma
apolipoprotein A-IV levels and coronary heart disease. Chin Medvolved in reverse cholesterol transport [17, 18], and its
J (Engl) 114:275–279, 2001overexpression in mice was recently demonstrated to be
7. Kronenberg F, Kuen E, Ritz E, et al: Apolipoprotein A-IV serum
associated with decreased atherosclerosis [19, 20]. We concentrations are elevated in mild and moderate renal failure. J
Am Soc Nephrol 13:461–469, 2002were able to show for the first time that low apoA-IV
8. Kronenberg F, Ko¨nig P, Neyer U, et al: Multicenter study ofconcentrations in humans are associated with coronary
lipoprotein(a) and apolipoprotein(a) phenotypes in patients with
artery disease in the general population [5]. In patients end-stage renal disease treated by hemodialysis or continuous am-
bulatory peritoneal dialysis. J Am Soc Nephrol 6:110–120, 1995with mild and moderate renal failure, we observed in
9. Kronenberg F, Lobentanz E-M, Ko¨nig P, et al: Effect of sampleeach stratum of renal impairment lower apoA-IV con-
storage on the measurement of lipoprotein(a), apolipoproteins
centrations in patients with atherosclerotic changes when B and A-IV, total and high-density lipoprotein cholesterol and
triglycerides. J Lipid Res 35:1318–1328, 1994compared to those without atherosclerosis [7]. When we
10. Dieplinger H, Schoenfeld PY, Fielding J: Plasma cholesterollook at the distribution of apoA-IV plasma concentrations
metabolism in end-stage renal disease: Difference between treat-
in hemodialysis and CAPD patients, we are able to ob- ment by hemodialysis or peritoneal dialysis. J Clin Invest 77:1071–
1083, 1986serve, in both patient groups, a considerable number of
11. Appel G: Lipid abnormalities in renal disease. Kidney Int 39:169–patients with unusually low apoA-IV concentrations for
183, 1991
dialysis patients. Whether these low levels predict the 12. London GM, Dru¨eke TB: Atherosclerosis and arteriosclerosis in
chronic renal failure. Kidney Int 51:1678–1695, 1997presence or future development of cardiovascular dis-
13. Kronenberg F, Neyer U, Lhotta K, et al: The low molecularease has yet to be determined in further studies.
weight apo(a) phenotype is an independent predictor for coronary
artery disease in hemodialysis patients: A prospective follow-up.
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